MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant

Dual Signaling of MyD88 and TRIF Is Critical for Maximal TLR4-Induced Dendritic Cell Maturation

(2014) H. Shen et al.   JOURNAL OF IMMUNOLOGY

The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine

(2012) S. L. Baldwin et al.   JOURNAL OF IMMUNOLOGY

Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A

(2012) Stacie L. Lambert et al.   PLoS One

Adjuvant solution for pandemic influenza vaccine production

(2012) C. H. Clegg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Selective TRIF-Dependent Signaling by a Synthetic Toll-Like Receptor 4 Agonist

(2012) W. S. Bowen et al.   Science Signaling

Humanized TLR4/MD-2 Mice Reveal LPS Recognition Differentially Impacts Susceptibility to Yersinia pestis and Salmonella enterica

(2012) Adeline M. Hajjar et al.   PLoS Pathogens

A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo

(2011) Austin Pantel et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant

(2011) Rhea N. Coler et al.   PLoS One

Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate

(2011) Hillarie Plessner Windish et al.   VACCINE

Applying TLR Synergy in Immunotherapy: Implications in Cutaneous Leishmaniasis

(2010) V. S. Raman et al.   JOURNAL OF IMMUNOLOGY

TLR4 Ligands Augment Antigen-Specific CD8+ T Lymphocyte Responses Elicited by a Viral Vaccine Vector

(2010) E. G. Rhee et al.   JOURNAL OF VIROLOGY

A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines

(2010) Rhea N. Coler et al.   PLoS One

A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis

(2010) S. Bertholet et al.   Science Translational Medicine

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations

(2009) Ryan C. Anderson et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Mechanism of action of clinically approved adjuvants

(2009) Bart N Lambrecht et al.   CURRENT OPINION IN IMMUNOLOGY

Vaccination with the ML0276 Antigen Reduces Local Inflammation but Not Bacterial Burden during Experimental Mycobacterium leprae Infection

(2009) V. S. Raman et al.   INFECTION AND IMMUNITY

Selective Activation of the p38 MAPK Pathway by Synthetic Monophosphoryl Lipid A

(2009) Caglar Cekic et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Enhanced humoral and Type 1 cellular immune responses with Fluzone® adjuvanted with a synthetic TLR4 agonist formulated in an emulsion

(2009) Susan L. Baldwin et al.   VACCINE

Intradermal immunization improves protective efficacy of a novel TB vaccine candidate

(2009) Susan L. Baldwin et al.   VACCINE

Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant

(2008) C. R. Casella et al.   CELLULAR AND MOLECULAR LIFE SCIENCES